Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SD 101

Drug Profile

SD 101

Alternative Names: SD-101

Latest Information Update: 26 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; University of California, Davis
  • Class Antineoplastics; Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma; Follicular lymphoma; Head and neck cancer; Lymphoma; Malignant melanoma
  • Phase I Haematological malignancies
  • No development reported Hepatitis C

Most Recent Events

  • 20 Oct 2018 Updated efficacy data from the phase I/II SYNERGY-001/KEYNOTE-184 trial in Malignant melanoma presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 04 Jun 2018 Updated efficacy and adverse events data from the phase I/II SYNERGY-001/KEYNOTE-184 trial in Malignant melanoma presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 17 May 2018 Additional efficacy and adverse events data from a phase Ib/II trial in Malignant melanoma and Head and neck cancer released by Dynavax Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top